

Stefan Siebert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3258719/publications.pdf>

Version: 2024-02-01

90
papers

3,445
citations

159358

30
h-index

155451

55
g-index

94
all docs

94
docs citations

94
times ranked

5468
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related “physician-reported spondylitis””. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e185-e185.	0.5	3
2	Examining the Relationship Between Rheumatoid Arthritis, Multimorbidity, and Adverse Health-Related Outcomes: A Systematic Review. <i>Arthritis Care and Research</i> , 2022, 74, 1500-1512.	1.5	16
3	Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study. <i>Rheumatology</i> , 2022, 61, 1026-1034.	0.9	15
4	Does Age Matter in Psoriatic Arthritis? A Narrative Review. <i>Journal of Rheumatology</i> , 2022, 49, 1085-1091.	1.0	13
5	The effect of exercise on cytokines: implications for musculoskeletal health: a narrative review. <i>BMC Sports Science, Medicine and Rehabilitation</i> , 2022, 14, 5.	0.7	51
6	Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830.	0.5	18
7	Frailty in rheumatoid arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank. <i>RMD Open</i> , 2022, 8, e002111.	1.8	9
8	Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, , jrheum.211337.	1.0	0
9	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266.	0.9	6
10	Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity “ a cross-sectional study. <i>Rheumatology</i> , 2021, 60, 1858-1862.	0.9	7
11	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 1588-1592.	0.9	4
12	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e337-e346.	2.2	24
13	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. <i>RMD Open</i> , 2021, 7, e001679.	1.8	19
14	Association of sarcopenia with incident osteoporosis: a prospective study of 168,682 UK biobank participants. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1179-1188.	2.9	26
15	TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis. <i>Trials</i> , 2021, 22, 433.	0.7	1
16	The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 941-952.	1.5	9
17	Estimating Cardiovascular Impacts of Drugs for Psoriatic Disease: A Long Way to Go. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2322-2325.	0.3	0
18	Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa063.	0.3	1

#	ARTICLE	IF	CITATIONS
19	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. <i>British Journal of Dermatology</i> , 2020, 182, 130-137.	1.4	52
20	Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis. <i>Rheumatology International</i> , 2020, 40, 375-381.	1.5	28
21	BRITSpA at five. <i>Rheumatology</i> , 2020, 59, 699-701.	0.9	0
22	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa043.	0.3	0
23	T cells and cytokines in inflamed psoriatic skin. Who's in charge?. <i>Immunology</i> , 2020, 160, 311-312.	2.0	3
24	JAK inhibitors and infections risk: focus on herpes zoster. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093605.	1.2	72
25	Patterns of multimorbidity and their effects on adverse outcomes in rheumatoid arthritis: a study of 5658 UK Biobank participants. <i>BMJ Open</i> , 2020, 10, e038829.	0.8	20
26	Treatment strategies in axial spondyloarthritis: what, when and how?. <i>Rheumatology</i> , 2020, 59, iv79-iv89.	0.9	41
27	Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features. <i>RMD Open</i> , 2020, 6, e001376.	1.8	31
28	The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?. <i>Current Opinion in Rheumatology</i> , 2020, 32, 349-356.	2.0	14
29	Examining the relationship between rheumatoid arthritis, multimorbidity and adverse health-related outcomes: A systematic review protocol. <i>Journal of Comorbidity</i> , 2020, 10, 2235042X2090665.	3.9	6
30	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition. <i>Medicine (United States)</i> , 2020, 99, e20458.	0.4	16
31	Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. <i>RMD Open</i> , 2020, 6, e001206.	1.8	11
32	Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. <i>Nature Reviews Rheumatology</i> , 2019, 15, 461-474.	3.5	95
33	Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. <i>PLoS Medicine</i> , 2019, 16, e1002739.	3.9	144
34	AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). <i>BMC Rheumatology</i> , 2019, 3, 19.	0.6	10
35	Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank. <i>Rheumatology</i> , 2019, 58, 2137-2142.	0.9	16
36	Responsiveness of Serum C-reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2019, 71, 1660-1669.	2.9	13

#	ARTICLE	IF	CITATIONS
37	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1437-1449.	2.9	77
38	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 281.	1.0	3
39	Comorbidity burden in axial spondyloarthritis: a cluster analysis. <i>Rheumatology</i> , 2019, 58, 1746-1754.	0.9	44
40	Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy. <i>Rheumatology and Therapy</i> , 2019, 6, 165-177.	1.1	32
41	JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, i43-i54.	0.9	221
42	Protocol for a multicentre randomised controlled parallel-group trial to compare the effectiveness of remotely delivered cognitive-behavioural and graded exercise interventions with usual care alone to lessen the impact of fatigue in inflammatory rheumatic diseases (LIFT). <i>BMJ Open</i> , 2019, 9, e026793.	0.8	9
43	Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review. <i>Rheumatology International</i> , 2019, 39, 187-201.	1.5	22
44	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2019, 46, 701-709.	1.0	21
45	Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1015-1018.	0.5	77
46	Rheumatoid arthritis and depression: an inflammatory perspective. <i>Lancet Psychiatry</i> , 2019, 6, 164-173.	3.7	238
47	The role of the immune system in kidney disease. <i>Clinical and Experimental Immunology</i> , 2018, 192, 142-150.	1.1	131
48	Services for spondyloarthritis: a survey of patients and rheumatologists. <i>Rheumatology</i> , 2018, 57, 987-996.	0.9	27
49	The extending scope of kinase inhibition in immune diseases. <i>Lancet</i> , 2018, 392, 2328-2331.	6.3	2
50	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , 2018, 57, 1982-1990.	0.9	26
51	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. <i>Scientific Reports</i> , 2017, 7, 40473.	1.6	32
52	Editorial: Choosing New Targets for Rheumatoid Arthritis Therapeutics: Too Interesting to Fail?. <i>Arthritis and Rheumatology</i> , 2017, 69, 1131-1134.	2.9	4
53	Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia. <i>Arthritis and Rheumatology</i> , 2017, 69, 2144-2150.	2.9	59
54	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing)	0.9	41

#	ARTICLE	IF	CITATIONS
55	Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0154515.	1.1	64
56	Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502â€¦649 UK Biobank participants. RMD Open, 2016, 2, e000267.	1.8	55
57	Web-based physiotherapy for people with axial spondyloarthritis (WEBPASS) â€“ a study protocol. BMC Musculoskeletal Disorders, 2016, 17, 360.	0.8	12
58	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 2016, 17, 461.	0.8	22
59	Brief Report: Predicting Functional Disability: Oneâ€™Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort. Arthritis and Rheumatology, 2016, 68, 1596-1602.	2.9	29
60	Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases. Annual Review of Medicine, 2016, 67, 337-353.	5.0	159
61	Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. Rheumatology, 2016, 55, 120-132.	0.9	32
62	Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods. Value in Health, 2015, 18, 425-431.	0.1	30
63	Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacological Reviews, 2015, 67, 280-309.	7.1	266
64	Severe flare as a predictor of poor outcome in ankylosing spondylitis: a cohort study using questionnaire and routine data linkage. Rheumatology, 2015, 54, 1563-1572.	0.9	16
65	The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data. PLoS ONE, 2015, 10, e0126105.	1.1	36
66	216.â€¢The Work-Related Costs of Ankylosing Spondylitis in a UK Cohort. Rheumatology, 2014, 53, i140-i141.	0.9	1
67	Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clinical and Experimental Immunology, 2014, 176, 1-10.	1.1	180
68	Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2290-2294.	1.0	48
69	Involving service users in trials: developing a standard operating procedure. Trials, 2013, 14, 219.	0.7	49
70	Qualitative research within trials: developing a standard operating procedure for a clinical trials unit. Trials, 2013, 14, 54.	0.7	56
71	Patient perspectives of managing fatigue in Ankylosing Spondylitis, and views on potential interventions: a qualitative study. BMC Musculoskeletal Disorders, 2013, 14, 163.	0.8	21
72	The effect of physical activity and motivation on function in ankylosing spondylitis: A cohort study. Seminars in Arthritis and Rheumatism, 2013, 42, 619-626.	1.6	48

#	ARTICLE	IF	CITATIONS
73	Fatigue in Ankylosing Spondylitis: Treatment Should Focus on Pain Management. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 361-367.	1.6	48
74	Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 1556-1562.	0.9	25
75	The information needs of people living with ankylosing spondylitis: a questionnaire survey. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 243.	0.8	42
76	HERALD (Health Economics using Routine Anonymised Linked Data). <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 24.	1.5	10
77	No Increased Rate of Acute Myocardial Infarction or Stroke Among Patients with Ankylosing Spondylitis—A Retrospective Cohort Study Using Routine Data. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 140-145.	1.6	68
78	HERALD (Health Economics using Routine Anonymised Linked Data). <i>Trials</i> , 2011, 12, .	0.7	0
79	Major flares as a diagnostic and prognostic measure when assessing ankylosing spondylitis severity. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 399-401.	0.3	1
80	Protocol for a population-based Ankylosing Spondylitis (PAS) cohort in Wales. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 197.	0.8	12
81	Frequency and characteristics of disease flares in ankylosing spondylitis. <i>Rheumatology</i> , 2010, 49, 929-932.	0.9	30
82	Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. <i>BMC Musculoskeletal Disorders</i> , 2008, 9, 4.	0.8	49
83	Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). <i>Rheumatology</i> , 2007, 47, 228-229.	0.9	14
84	Cytokine Production by Hepatic Anaplastic Large-Cell Lymphoma Presenting as a Rheumatic Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 63-67.	1.6	30
85	Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. <i>Arthritis and Rheumatism</i> , 2005, 52, 1287-1292.	6.7	58
86	Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF- κ B activation due to decreased surface expression. <i>FEBS Letters</i> , 2005, 579, 5193-5198.	1.3	46
87	Proptosis can be the presenting feature of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 908-909.	0.5	14
88	Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. <i>FEBS Letters</i> , 2004, 570, 138-142.	1.3	7
89	Clinical images: Brown's syndrome: an unusual case of diplopia in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2460-2460.	6.7	2
90	Frailty in people with rheumatoid arthritis: a systematic review of observational studies. <i>Wellcome Open Research</i> , 0, 6, 244.	0.9	2